Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China.

ABSTRACT:

Objectives

There is limited data on the unmet needs of advanced non-small cell lung cancer (aNSCLC) patients with epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) in China. The single-arm CHRYSALIS study (NCT02609776) demonstrated durable responses of amivantamab monotherapy among aNSCLC patients with EGFR exon20ins after platinum-based chemotherapy. We aimed to leverage real-world data to describe the unmet needs of these patients and explore the clinical benefits of amivantamab monotherapy through indirect comparison to an external control (EC) from China.

Materials and methods

Eligible patients with any systemic anti-cancer therapy (SACT) after the aNSCLC diagnosis were identified from the electronic medical records of three tertiary medical i

SUBMITTER: Shen L 

PROVIDER: S-EPMC12315348 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature